Diana Zuckerman

Last updated
Diana Zuckerman
Diana Zuckerman Headshot.png
BornJune 17, 1950
NationalityAmerican
Education Smith College(B.A)
Ohio State University (Ph.D)

Diana M. Zuckerman (born 16 June 1950 [1] ) is an American health policy analyst who focuses on the implications of policies for public health and patients' health. She specializes in national health policy, particularly in women's health and the safety and effectiveness of medical products. She is the President of the National Center for Health Research (formerly National Research Center for Women & Families) and the Cancer Prevention and Treatment Fund. [2]

Contents

Early life and education

Zuckerman earned her B.A. in psychology from Smith College and then obtained a Ph.D. in psychology from the Ohio State University in 1977. At Yale Medical School she was a post-doctoral fellow in epidemiology and public health from 1979 to 1980.

Career

She was on the faculty at Vassar College and Yale University, and directed a longitudinal study of college students as director of the Seven College Study at Harvard University, publishing books and articles on the impact of media on children, the impact of religion on the health of the elderly, and how women's life experiences influence their mental and physical health. She left academia in 1983 when she was selected as a Fellow in the American Association for the Advancement of Science Congressional Science Fellowship program. [3]

From 1985 to 1993 she worked at the U.S. Congress in a House subcommittee where she was responsible for a dozen Congressional oversight investigations on health and social policy, including political manipulation of government grants to prevent child abuse, lack of safeguards for infertility treatments, financial conflicts of interest among National Institutes of Health (NIH) grant recipients, and the lack of safety studies on breast implants. Information from the hearings received widespread public health, government, and media attention, resulting in several policy and regulatory changes, including the U.S. Food and Drug Administration (FDA) requiring implant manufacturers to submit safety studies for the first time. [3]

In 1993, Zuckerman joined the staff of the Senate Veterans Affairs Committee and began an investigation that resulted in the first Congressional hearings focused on the possible causes of Gulf War syndrome. In 1995 she was a senior policy advisor in the Clinton Administration. From 1996, she undertook leading roles in non-profit organizations, including, from 1999, presidency of the National Research Center for Women & Families [3] (renamed the National Center for Health Research in 2014) and The Cancer Prevention and Treatment Fund.

Her work focuses on improving the quality of medical products and healthcare in the United States. She has been highly critical of scientific and medical research paid for by companies, who then use this to promote their products, as well as the lack of media coverage on independently funded research that challenges industry-funded research. She has said:

You've heard of junk science a term coined by corporations to describe research they don't like but the real danger to public health might be called "checkbook science": research intended not to expand knowledge or to benefit humanity, but instead to sell products. [4]

In February 2011, Zuckerman and colleagues Paul Brown and Dr. Steven Nissen published a study in the peer-reviewed journal Archives of Internal Medicine , which evaluated the FDA's recalls of devices that the agency considered potentially deadly or otherwise very high risk. [5] Based on FDA data, the authors determined that most of the devices that were high-risk recalls had never been studied in clinical trials prior to FDA approval, and that the FDA needed to use more stringent criteria for implanted medical devices and those used to diagnose serious illnesses, and an editorial in the same issue agreed. [6] [7] [8] [9] In April 2011, Zuckerman presented the results of the study at a hearing by the U.S. Senate Special Committee on Aging. [10]

Zuckerman is the author of five books, several book chapters, and dozens of articles in medical and academic journals, and in newspapers across the country. Her policy work has resulted in news coverage on all the major TV networks, including ABC, CBS, NBC, CNN, Fox News, public television, 60 Minutes , 20/20 , National Public Radio, and in major U.S. print media such as The New York Times , [11] [12] [13] [14] The Washington Post , [15] The Washington Times , Los Angeles Times , [16] The Boston Globe , [17] [18] USA Today , Detroit Free Press , New York Daily News , Newsweek , Time , U.S. News & World Report , Family Circle , The New Yorker , Glamour , Self , [19] as well as many other newspapers, magazines, and radio programs. [20] [21] [22]

Published articles

Zuckerman frequently writes articles regarding medical drugs and devices, as well as public health policy. Recent articles published in peer-reviewed journals include:

Related Research Articles

<span class="mw-page-title-main">Biomedical engineering</span> Application of engineering principles and design concepts to medicine and biology

Biomedical engineering (BME) or medical engineering is the application of engineering principles and design concepts to medicine and biology for healthcare purposes. BME is also traditionally logical sciences to advance health care treatment, including diagnosis, monitoring, and therapy. Also included under the scope of a biomedical engineer is the management of current medical equipment in hospitals while adhering to relevant industry standards. This involves procurement, routine testing, preventive maintenance, and making equipment recommendations, a role also known as a Biomedical Equipment Technician (BMET) or as a clinical engineer.

<span class="mw-page-title-main">Food and Drug Administration</span> United States federal agency

The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.

<span class="mw-page-title-main">Emergency contraception</span> Birth control measures taken after sexual intercourse

Emergency contraception (EC) is a birth control measure, used after sexual intercourse to prevent pregnancy.

An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by the conditions. The conditions that orphan drugs are used to treat are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy that depends on the legislation of the country.

<span class="mw-page-title-main">Breast augmentation</span> Surgical procedure

Breast augmentation and augmentation mammoplasty is a cosmetic surgery technique using breast-implants and fat-graft mammoplasty techniques to increase the size, change the shape, and alter the texture of the breasts. Augmentation mammoplasty is applied to correct congenital defects of the breasts and the chest wall. As an elective cosmetic surgery, primary augmentation changes the aesthetics – of size, shape, and texture – of healthy breasts.

<span class="mw-page-title-main">Federal Food, Drug, and Cosmetic Act</span> Acts of the United States Congress

The United States Federal Food, Drug, and Cosmetic Act is a set of laws passed by the United States Congress in 1938 giving authority to the U.S. Food and Drug Administration (FDA) to oversee the safety of food, drugs, medical devices, and cosmetics. The FDA's principal representative with members of congress during its drafting was Charles W. Crawford. A principal author of this law was Royal S. Copeland, a three-term U.S. senator from New York. In 1968, the Electronic Product Radiation Control provisions were added to the FD&C. Also in that year the FDA formed the Drug Efficacy Study Implementation (DESI) to incorporate into FD&C regulations the recommendations from a National Academy of Sciences investigation of effectiveness of previously marketed drugs. The act has been amended many times, most recently to add requirements about bioterrorism preparations.

<span class="mw-page-title-main">Medical device</span> Device to be used for medical purposes

A medical device is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the device in their country. As a general rule, as the associated risk of the device increases the amount of testing required to establish safety and efficacy also increases. Further, as associated risk increases the potential benefit to the patient must also increase.

An adverse effect is an undesired harmful effect resulting from a medication or other intervention, such as surgery. An adverse effect may be termed a "side effect", when judged to be secondary to a main or therapeutic effect. The term complication is similar to adverse effect, but the latter is typically used in pharmacological contexts, or when the negative effect is expected or common. If the negative effect results from an unsuitable or incorrect dosage or procedure, this is called a medical error and not an adverse effect. Adverse effects are sometimes referred to as "iatrogenic" because they are generated by a physician/treatment. Some adverse effects occur only when starting, increasing or discontinuing a treatment. Using a drug or other medical intervention which is contraindicated may increase the risk of adverse effects. Adverse effects may cause complications of a disease or procedure and negatively affect its prognosis. They may also lead to non-compliance with a treatment regimen. Adverse effects of medical treatment resulted in 142,000 deaths in 2013 up from 94,000 deaths in 1990 globally.

<span class="mw-page-title-main">Ethicon</span> Pharmaceutical company

Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line.

<span class="mw-page-title-main">Implant (medicine)</span> Device surgically placed within the body for medical purposes

An implant is a medical device manufactured to replace a missing biological structure, support a damaged biological structure, or enhance an existing biological structure. For example, an implant may be a rod, used to strengthen weak bones. Medical implants are human-made devices, in contrast to a transplant, which is a transplanted biomedical tissue. The surface of implants that contact the body might be made of a biomedical material such as titanium, silicone, or apatite depending on what is the most functional. In 2018, for example, American Elements developed a nickel alloy powder for 3D printing robust, long-lasting, and biocompatible medical implants. In some cases implants contain electronics, e.g. artificial pacemaker and cochlear implants. Some implants are bioactive, such as subcutaneous drug delivery devices in the form of implantable pills or drug-eluting stents.

<span class="mw-page-title-main">David A. Kessler</span> American pediatrician & attorney (born 1951)

David Aaron Kessler is an American pediatrician, attorney, author, and administrator serving as Chief Science Officer of the White House COVID-19 Response Team since 2021. Kessler was the commissioner of the Food and Drug Administration (FDA) from November 8, 1990, to February 28, 1997. He co-chaired the Biden-Harris transition’s COVID-19 Advisory Board from November 2020 to January 2021 and was the head of Operation Warp Speed, the U.S. government program to accelerate the development of COVID-19 vaccines and other treatments, from January to February 2021.

<span class="mw-page-title-main">Breast implant</span> Prosthesis used to change the size, shape, and contour of a persons breast

A breast implant is a prosthesis used to change the size, shape, and contour of a person's breast. In reconstructive plastic surgery, breast implants can be placed to restore a natural looking breast following a mastectomy, to correct congenital defects and deformities of the chest wall or, cosmetically, to enlarge the appearance of the breast through breast augmentation surgery.

<span class="mw-page-title-main">FDA Center for Devices and Radiological Health</span>

The Center for Devices and Radiological Health (CDRH) is the branch of the United States Food and Drug Administration (FDA) responsible for the premarket approval of all medical devices, as well as overseeing the manufacturing, performance and safety of these devices. The CDRH also oversees the radiation safety performance of non-medical devices which emit certain types of electromagnetic radiation, such as cellular phones and microwave ovens.

<span class="mw-page-title-main">National Center for Health Research</span> Organization

The National Center for Health Research is a Washington, D.C.-based non-profit organization founded in 1999, providing health-related services such as providing free information and training based on research findings; educating policy makers and working with the media. The President of the organisation is Diana Zuckerman. The primary program is The Cancer Prevention and Treatment Fund, which utilises an online health hotline.

A pivotal trial is typically a Phase III clinical trial in the multi-year process of clinical research intended to demonstrate and confirm the safety and efficacy of a treatment – such as a drug candidate, medical device or clinical diagnostic procedure – and to estimate the incidence of common adverse effects. A successful pivotal trial is required as evidence for drug marketing approval by the relevant approval authorities, such as the European Medicines Agency, Health Canada or United States Food and Drug Administration (FDA).

Implant failure refers to the failure of any medical implant to meet the claims of its manufacturer or the health care provider involved in its installation. Implant failure can have any number of causes. The rates of failure vary for different implants.

Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.

<span class="mw-page-title-main">Janet Woodcock</span> American physician

Janet Woodcock is an American physician serving as Principal Deputy Commissioner of Food and Drugs, having previously served as Acting Commissioner of the U.S. Food and Drug Administration (FDA). She joined the FDA in 1986, and has held a number of senior leadership positions there, including terms as the Director of Center for Drug Evaluation and Research (CDER) from 1994 to 2004 and 2007 to 2021.

Due to the many regulations in the industry, the design of medical devices presents significant challenges from both engineering and legal perspectives.

References

  1. http://authorities.loc.gov/cgi-bin/Pwebrecon.cgi?AuthRecID=3305166&v1=1&HC=1&SEQ=20071211042258&PID=27945 [ full citation needed ]
  2. "Stop Cancer Fund - Information you can use. A voice you can trust". stopcancerfund.org. Retrieved April 11, 2017.
  3. 1 2 3 National Research Center for Women & Families staff listing Retrieved June 14, 2010.
  4. Zuckerman, Diana (2002)Hype in health reporting Archived 2006-05-23 at the Wayback Machine . Retrieved August 16, 2006.
  5. Zuckerman DM, Brown P, Nissen SE (June 2011). "Medical device recalls and the FDA approval process". Archives of Internal Medicine. 171 (11): 1006–11. doi: 10.1001/archinternmed.2011.30 . PMID   21321283.
  6. Redberg RF, Dhruva SS (June 2011). "Medical device recalls: get it right the first time: Comment on "Medical device recalls and the FDA approval process"". Archives of Internal Medicine. 171 (11): 1011–2. doi:10.1001/archinternmed.2011.27. PMID   21321286.
  7. "Not enough safety testing on medical implant devices, studies claim". cbsnews.com. CBS News. September 30, 2014. Retrieved April 11, 2017.
  8. Thomas M. Burton (September 29, 2014). "Medical Devices Lack Safety Evidence, Study Finds". The Wall Street Journal . Retrieved April 11, 2017.
  9. "Studies criticize U.S. medical device approval process". Reuters . September 30, 2014. Retrieved April 11, 2017.
  10. "A Delicate Balance: FDA and the Reform of the Medical Device Approval Process". 13 April 2011.
  11. Gardiner Harris (April 8, 2009). "F.D.A. to Check Safety of Old Devices". The New York Times . Retrieved April 11, 2017.
  12. Reed Abelson (October 27, 2009). "Quickly Vetted, Treatment Is Offered to Patients". The New York Times. Retrieved April 11, 2017.
  13. Ronio Caryn Rabin (May 3, 2015). "Long-Term Data on Complications Adds to Criticism of Essure Contraceptive Implant". The New York Times. Retrieved April 11, 2017.
  14. Marshall Allen; Olga Pierce (February 6, 2015). "Knee Replacement Device Unapproved, but Used in Surgery". The New York Times. Retrieved April 11, 2017.
  15. "Implant Maker Fixed Samples Only". The Washington Post . December 4, 2005. Retrieved April 11, 2017.
  16. "Breast implants: FDA stands by silicone implants". Los Angeles Times . June 23, 2011. Retrieved April 11, 2017.
  17. "Hip implants a bit more likely to fail in women". The Boston Globe . Associated Press. February 19, 2013. Retrieved April 11, 2017.
  18. "FDA panel supports firm's breast implant". boston.com. Retrieved April 11, 2017.
  19. SELF Staffers (January 26, 2011). "The True Price of Cheap Cosmetic Surgery". SELF . Retrieved April 11, 2017.
  20. "Key Staff". National Center for Health Research . Retrieved April 11, 2017.
  21. "Are Breast Implants Safe?". Medscape . Retrieved April 11, 2017.
  22. "FDA Reviewing Safety of Essure Birth Control Implant". The New York Times . Archived from the original on 2015-09-25. Retrieved 2017-02-24.